GE
GELS.US Gelteq Limited Ordinary Shares
- Market cap
- USD 4.07M
- P/E
- -
- P/B
- 0.44x
- ROE
- -52.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Mar 2026.
Is GELS.US undervalued?
Graham numberThe Graham number of Gelteq Limited Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gelteq Limited Ordinary Shares fundamental analysis
No fundamental analysis for Gelteq Limited Ordinary Shares yet.
Gelteq Limited Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Full company profileGelteq Limited Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gelteq Limited Ordinary Shares annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 148K | 79.8K | 0.00 | 166K | 357K |
| Gross Profit | - | 0.00 | 52.7K | 30.9K | 0.00 | 166K | 357K |
| Operating Income | - | -648K | -3.19M | -3.10M | -2.95M | -5.50M | -7.09M |
| EBITDA | -527K | -590K | -1.98M | -1.90M | -1.80M | -3.48M | -5.85M |
| Net Income | -376K | -649K | -3.37M | -3.51M | -3.55M | -6.65M | -7.48M |
| EPS | -0.16 | -0.07 | -0.36 | -0.37 | -0.38 | -0.66 | -0.71 |
| Balance Sheet | |||||||
| Total Assets | 619K | 24.2M | 23.4M | 22.5M | 20.8M | 21.5M | 20.1M |
| Total Liabilities | 396K | 403K | 2.55M | 3.84M | 5.65M | 5.67M | 5.92M |
| Shareholders' Equity | 223K | 23.8M | 20.9M | 18.7M | 15.1M | 15.8M | 14.2M |
| Cash & Short-term Investments | 320K | 182K | 162K | 399K | 24.5K | 345K | 9.35K |
| Total Debt | 171K | 172K | 1.51M | 2.49M | 3.84M | 4.22M | 5.11M |
| Cash Flow | |||||||
| Operating Cash Flow | - | - | - | -1.77M | -1.07M | -5.52M | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 75.9K | 148K | 642K | - |
| Free Cash Flow | -354K | -277K | -1.51M | -1.85M | -1.22M | -6.16M | - |
| Ratios | |||||||
| ROE | -168.4% | -2.7% | -16.2% | -18.8% | -23.5% | -42.0% | -52.7% |
| ROA | -60.7% | -2.7% | -14.4% | -15.6% | -17.1% | -30.9% | -37.2% |
| Net Profit Margin | - | - | -2,283.4% | -4,391.4% | - | -4,011.9% | -2,095.3% |
| Debt to Equity | 0.77x | 0.01x | 0.07x | 0.13x | 0.25x | 0.27x | 0.36x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gelteq Limited Ordinary Shares dividends
Gelteq Limited Ordinary Shares has not paid dividends in the last 6 fiscal years.
Who owns Gelteq Limited Ordinary Shares
- Insiders 47.53%
- Institutions 0.98%
- Public & others 51.49%
- Shares outstanding 10.7M
- Free float 5.15M
Top institutions holding GELS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TWO SIGMA SECURITIES, LLC | 33.2K | 0.31% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 30.2K | 0.28% | 0.00% | Jun 2026 |
| Wedbush Morgan Securities Inc | 20.0K | 0.19% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 15.0K | 0.14% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 11.5K | 0.11% | -17.16% | Jun 2026 |
| UBS Group AG | 125.00 | 0.00% | -93.18% | Jun 2026 |
| Private Advisor Group, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Two Sigma Investments LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Gelteq Limited Ordinary Shares company profile
- Company name
- Gelteq Limited Ordinary Shares
- Ticker
- GELS.US
- ISIN
- AU0000218109
- Exchange
- USA Stocks
- Listed since
- Oct 29, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7
- Fiscal year end
- June
- Address
- Monash Innovation Labs, Clayton, VIC, Australia, 3800
- Phone
- 61 3 9087 3990
- Website
- gelteq.com
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Gelteq Limited Ordinary Shares management
7- Mr. Nathan Jacob GivoniCo-Founder, CEO & Executive Director · born 1984
- Mr. Simon Hayden SzewachCo-Founder & Non-Executive Chairman · born 1980
- Ms. Thuy-Linh GiglerChief Financial Officer · born 1980
- Dr. Paul M. Wynne Ph.D.Chief Scientific Officer · born 1963
- Bradley Glenn KarpHead of Sales & Marketing
- Mr. Adam BendellPresident of U.S. Operations
- Mr. Matthew JonesHead of Sports Performance